Assessing late images in PET-CT for bladder cancer staging
Intérêt Des Images Tardives Pour le Bilan d'Extensions en TEP-TDM au 18FGD Des Cancers de Vessie Infiltrant le Muscle (TARDITEP)
This study is testing if taking later images during a PET-CT scan can help better identify lymph node involvement in patients with muscle-invasive bladder cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 66 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hopital Foch Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Suresnes, Île-de-France Region) |
| Trial ID | NCT06537960 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of late FDG-PET images in improving the sensitivity of lymph node staging in patients with muscle-invasive bladder cancer. It compares the results of standard PET images taken one hour after radiotracer injection with those taken 2.5 hours later. Patients will undergo 18FDG PET-CT scans at Hôpital Foch, where their fasting status and blood glucose levels will be monitored prior to the procedure. The study focuses on patients with histologically confirmed muscle-invasive bladder cancer who are scheduled for initial extension workup.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically proven muscle-invasive bladder cancer scheduled for 18FDG PET-CT.
Not a fit: Patients with a history of pelvic or genitourinary cancer, known metastatic disease, or contraindications to 18FDG PET-CT may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate staging of bladder cancer, potentially improving treatment outcomes.
How similar studies have performed: While this approach is innovative, similar studies have not been extensively documented, indicating a potential for novel findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient 18 years of age or older, * With histologically proven muscle-invasive bladder cancer (≥pT2) at endoscopic bladder resection, * Scheduled to undergo 18FDG PET-CT in the nuclear medicine department at Hôpital Foch, * Having signed a consent form, * Affiliated to a health insurance scheme. Exclusion Criteria: * Patient with a history of pelvic or genitourinary cancer, * Patient with known metastatic disease, * Patient with a contraindication to 18FDG PET-CT, * Pregnant or breast-feeding woman, * Patient deprived of liberty or under guardianship.
Where this trial is running
Suresnes, Île-de-France Region
- Hopital Foch — Suresnes, Île-de-France Region, France (Recruiting)
Study contacts
- Study coordinator: MARC BERTAUX, Dr
- Email: drci.promotion@hopital-foch.com
- Phone: 00 33 1 46 25 11 94
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.